Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28592067 | 0.78 | BRAF (0.36) | BRAFIDO1 | |
| SCHEMBL17645374 | 0.77 | GHSR (0.33) | BRAFIDO1 | |
| SCHEMBL28402453 | 0.73 | ADORA2A (0.40) | BRAFIDO1 | |
| SCHEMBL17645458 | 0.73 | TGFBR1 (0.33) | BRAFIDO1 | |
| SCHEMBL17645420 | 0.71 | PROKR1 (0.32) | BRAF | |
| SCHEMBL17645165 | 0.71 | TGFBR1 (0.38) | — | |
| SCHEMBL24999541 | 0.70 | MAPK14 (0.42) | BRAFFGFR2 | |
| SCHEMBL17645435 | 0.70 | TGFBR1 (0.45) | — | |
| SCHEMBL28586158 | 0.69 | SLC6A4 (0.39) | — | |
| SCHEMBL17645358 | 0.69 | TGFBR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204377-B1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | TGFBR1, TGFBR2, PDGFRB | BRAF 131/4885IDO1 841/4885FGFR2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.